Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success with two ...

The trial will be a collaborative effort between the company, the Norwegian Cancer Society, and Cancer Research UK.

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Amtagvi® and its accompanying design marks, Proleukin ®, Iovance ®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.